|
1
|
Ohgaki H and Kleihues P: Epidemiology and
etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Perry A, Burger P, Ellison DW,
Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP,
Eberhart C, et al: International society of neuropathology-haarlem
consensus guidelines for nervous system tumor classification and
grading. Brain Pathol. 24:429–435. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carlsson SK, Brothers SP and Wahlestedt C:
Emerging treatment strategies for glioblastoma multiforme. EMBO Mol
Med. 6:1359–1370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gilbert MR, Friedman HS, Kuttesch JF,
Prados MD, Olson JJ, Reaman GH and Zaknoen SL: A phase II study of
temozolomide in patients with newly diagnosed supratentorial
malignant glioma before radiation therapy. Neuro Oncol. 4:261–267.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Villano JL, Seery TE and Bressler LR:
Temozolomide in malignant gliomas: Current use and future targets.
Cancer Chemother Pharmacol. 64:647–655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roos WP, Batista LF, Naumann SC, Wick W,
Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells
triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacinto FV and Esteller M: MGMT
hypermethylation: A prognostic foe, a predictive friend. DNA Repair
(Amst). 6:1155–1160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spiegl-Kreinecker S, Pirker C, Filipits M,
Lötsch D, Buchroithner J, Pichler J, Silye R, Weis S, Micksche M,
Fischer J and Berger W: O6-Methylguanine DNA methyltransferase
protein expression in tumor cells predicts outcome of temozolomide
therapy in glioblastoma patients. Neuro Oncol. 12:28–36. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bobola MS, Alnoor M, Chen JY, Kolstoe DD,
Silbergeld DL, Rostomily RC, Blank A, Chamberlain MC and Silber JR:
O6-methylguanine-DNA methyltransferase activity is associated with
response to alkylating agent therapy and with MGMT promoter
methylation in glioblastoma and anaplastic glioma. BBA Clin.
3:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vlachostergios PJ, Hatzidaki E and
Papandreou CN: MGMT repletion after treatment of glioblastoma cells
with temozolomide and O6-benzylguanine implicates NFκB and mutant
p53. Neurol Res. 35:879–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bocangel D, Sengupta S, Mitra S and Bhakat
KK: p53-mediated down-regulation of the human DNA repair gene
O6-methylguanine-DNA methyltransferase (MGMT) via interaction with
Sp1 transcription factor. Anticancer Res. 29:3741–3750.
2009.PubMed/NCBI
|
|
13
|
Pyko IV, Nakada M, Sabit H, Teng L,
Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS and
Hamada J: Glycogen synthase kinase 3β inhibition sensitizes human
glioblastoma cells to temozolomide by affecting O6-methylguanine
DNA methyltransferase promoter methylation via c-Myc signaling.
Carcinogenesis. 34:2206–2217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okada M, Sato A, Shibuya K, Watanabe E,
Seino S, Suzuki S, Seino M, Narita Y, Shibui S, Kayama T and
Kitanaka C: JNK contributes to temozolomide resistance of stem-like
glioblastoma cells via regulation of MGMT expression. Int J Oncol.
44:591–599. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang H, Lin H, Zhang X and Li J:
Resveratrol reverses temozolomide resistance by downregulation of
MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Oncol Rep. 27:2050–2056. 2012.PubMed/NCBI
|
|
16
|
Senftleben U and Karin M: The
IKK/NF-kappaB pathway. Crit Care Med. 30 (1 Supp):S18–S26. 2002.
View Article : Google Scholar
|
|
17
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayden MS and Ghosh S: Regulation of NF-κB
by TNF family cytokines. Semin Immunol. 26:253–266. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rayet B and Gélinas C: Aberrant rel/nfkb
genes and activity in human cancer. Oncogene. 18:6938–6947. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: From innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Annunziata CM, Davis RE, Demchenko Y,
Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W,
et al: Frequent engagement of the classical and alternative
NF-kappaB pathways by diverse genetic abnormalities in multiple
myeloma. Cancer Cell. 12:115–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng ZX, Sun B, Wang SJ, Gao Y, Zhang YM,
Zhou HX, Jia G, Wang YW, Kong R, Pan SH, et al: Nuclear
factor-κB-dependent epithelial to mesenchymal transition induced by
HIF-1α activation in pancreatic cancer cells under hypoxic
conditions. PLoS One. 6:e237522011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garner JM, Fan M, Yang CH, Du Z, Sims M,
Davidoff AM and Pfeffer LM: Constitutive activation of signal
transducer and activator of transcription 3 (STAT3) and nuclear
factor κB signaling in glioblastoma cancer stem cells regulates the
Notch pathway. J Biol Chem. 288:26167–26176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huber MA, Azoitei N, Baumann B, Grünert S,
Sommer A, Pehamberger H, Kraut N, Beug H and Wirth T: NF-kappaB is
essential for epithelial-mesenchymal transition and metastasis in a
model of breast cancer progression. J Clin Invest. 114:569–581.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng ZX, Wang DW, Liu T, Liu WX, Xia WB,
Xu J, Zhang YH, Qu YK, Guo LQ, Ding L, et al: Effects of the HIF-1α
and NF-κB loop on epithelial-mesenchymal transition and
chemoresistance induced by hypoxia in pancreatic cancer cells.
Oncol Rep. 31:1891–1898. 2014.PubMed/NCBI
|
|
26
|
Puliyappadamba VT, Hatanpaa KJ,
Chakraborty S and Habib AA: The role of NF-kappaB in the
pathogenesis of glioma. Mol Cell Oncol. 1:e9634782014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Caporali S, Levati L, Graziani G, Muzi A,
Atzori MG, Bonmassar E, Palmieri G, Ascierto PA and D'Atri S: NF-κB
is activated in response to temozolomide in an AKT-dependent manner
and confers protection against the growth suppressive effect of the
drug. J Transl Med. 10:2522012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lavon I, Fuchs D, Zrihan D, Efroni G,
Zelikovitch B, Fellig Y and Siegal T: Novel mechanism whereby
nuclear factor kappaB mediates DNA damage repair through regulation
of O(6)-methylguanine-DNA-methyltransferase. Cancer Res.
67:8952–8959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weaver KD, Yeyeodu S, Cusack JC Jr,
Baldwin AS Jr and Ewend MG: Potentiation of chemotherapeutic agents
following antagonism of nuclear factor kappa B in human gliomas. J
Neurooncol. 61:187–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee DW, Ramakrishnan D, Valenta J, Parney
IF, Bayless KJ and Sitcheran R: The NF-κB RelB protein is an
oncogenic driver of mesenchymal glioma. PLoS One. 8:e574892013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Wei B, Hu G, Wang L, Bi M, Sun Z
and Jin Y: Screening of differentially expressed genes associated
with human glioblastoma and functional analysis using a DNA
microarray. Mol Med Rep. 12:1991–1996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Wang H, Zhang W, Huang HJ, Liao WS
and Fuller GN: Analysis of the activation status of Akt, NFkappaB,
and Stat3 in human diffuse gliomas. Lab Invest. 84:941–951. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun P, Mu Y and Zhang S: A novel
NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma
promoted by Bmi-1. Tumour Biol. 35:12721–12727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Banerjee S, Li Y, Rahman KM, Zhang
Y and Sarkar FH: Down-regulation of notch-1 inhibits invasion by
inactivation of nuclear factor-kappaB, vascular endothelial growth
factor, and matrix metalloproteinase-9 in pancreatic cancer cells.
Cancer Res. 66:2778–2784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang CY, Cusack JC Jr, Liu R and Baldwin
AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor
therapy through increased apoptosis by inhibition of NF-kappaB. Nat
Med. 5:412–417. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim HJ, Hawke N and Baldwin AS: NF-kappaB
and IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Jia L, Jin X, Liu Q, Cao W, Gao X,
Yang M and Sun B: NF-κB inhibitor reverses temozolomide resistance
in human glioma TR/U251 cells. Oncol Lett. 9:2586–2590.
2015.PubMed/NCBI
|
|
38
|
Zhang L, Ren X, Cheng Y, Liu X, Allen JE,
Zhang Y, Yuan Y, Huang SY, Yang W, Berg A, et al: The NFκB
inhibitor, SN50, induces differentiation of glioma stem cells and
suppresses their oncogenic phenotype. Cancer Biol Ther. 15:602–611.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qin JD, Cao ZH, Li XF, Kang XL, Xue Y, Li
YL, Zhang D, Liu XY and Xue YZ: Effect of ammonium pyrrolidine
dithiocarbamate (PDTC) on NF-κB activation and CYP2E1 content of
rats with immunological liver injury. Pharm Biol. 52:1460–1466.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kan S, Zhou H, Jin C and Yang H: Effects
of PDTC on NF-κB expression and apoptosis in rats with severe acute
pancreatitis-associated lung injury. Int J Clin Exp Med.
8:3258–3270. 2015.PubMed/NCBI
|
|
41
|
Zhang JJ, Xu ZM, Zhang CM, Dai HY, Ji XQ,
Wang XF and Li C: Pyrrolidine dithiocarbamate inhibits nuclear
factor-κB pathway activation, and regulates adhesion, migration,
invasion and apoptosis of endometriotic stromal cells. Mol Hum
Reprod. 17:175–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gu JW, Young E, Busby B, Covington J and
Johnson JW: Oral administration of pyrrolidine dithiocarbamate
(PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of
breast cancer in female mice. Cancer Biol Ther. 8:514–521. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lan F, Yang Y, Han J, Wu Q, Yu H and Yue
X: Sulforaphane reverses chemo-resistance to temozolomide in
glioblastoma cells by NF-κB-dependent pathway downregulating MGMT
expression. Int J Oncol. 48:559–568. 2016.PubMed/NCBI
|
|
44
|
Song T, Li H, Tian Z, Xu C, Liu J and Guo
Y: Disruption of NF-κB signaling by fluoxetine attenuates MGMT
expression in glioma cells. Onco Targets Ther. 8:2199–2208.
2015.PubMed/NCBI
|
|
45
|
Fritz G, Tano K, Mitra S and Kaina B:
Inducibility of the DNA repair gene encoding O6-methylguanine-DNA
methyltransferase in mammalian cells by DNA-damaging treatments.
Mol Cell Biol. 11:4660–4668. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rauert-Wunderlich H, Siegmund D, Maier E,
Giner T, Bargou RC, Wajant H and Stühmer T: The IKK inhibitor Bay
11–7082 induces cell death independent from inhibition of
activation of NFκB transcription factors. PLoS One. 8:e592922013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Opferman JT: Attacking cancer's Achilles
heel: Antagonism of anti-apoptotic BCL-2 family members. FEBS J.
283:2661–2675. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wall NR, Beck FW, Al-Katib AM and Mohammad
RM: Treatment-induced expression of anti-apoptotic proteins in
WSU-CLL, a human chronic lymphocytic leukemia cell line. J Drug
Target. 9:329–339. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zaanan A, Okamoto K, Kawakami H, Khazaie
K, Huang S and Sinicrope FA: The mutant KRAS Gene Up-regulates
BCL-XL protein via STAT3 to confer apoptosis resistance that is
reversed by BIM protein induction and BCL-XL antagonism. J Biol
Chem. 290:23838–23849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Plewka D, Jakubiec-Bartnik B, Morek M,
Bogunia E, Bienioszek M, Wolski H, Kotrych D, Dziekan K,
Seremak-Mrozikiewicz A and Plewka A: Survivin in ovary tumors.
Ginekol Pol. 86:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhou W, Xu J, Gelston E, Wu X, Zou Z, Wang
B, Zeng Y, Wang H, Liu A, Xu L and Liu Q: Inhibition of Bcl-xL
overcomes polyploidy resistance and leads to apoptotic cell death
in acute myeloid leukemia cells. Oncotarget. 6:21557–21571. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vallianou NG, Evangelopoulos A, Schizas N
and Kazazis C: Potential anticancer properties and mechanisms of
action of curcumin. Anticancer Res. 35:645–651. 2015.PubMed/NCBI
|
|
53
|
Shukla S, Shankar E, Fu P, MacLennan GT
and Gupta S: Suppression of NF-κB and NF-κB-regulated gene
expression by apigenin through IκBα and IKK pathway in TRAMP mice.
PLoS One. 10:e01387102015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bravatà V, Minafra L, Russo G, Forte GI,
Cammarata FP, Ripamonti M, Casarino C, Augello G, Costantini F,
Barbieri G, et al: High-dose ionizing radiation regulates gene
expression changes in the MCF7 breast cancer cell line. Anticancer
Res. 35:2577–2591. 2015.PubMed/NCBI
|
|
55
|
Kunami N, Katsuya H, Nogami R, Ishitsuka K
and Tamura K: Promise of combining a Bcl-2 family inhibitor with
bortezomib or SAHA for adult T-cell leukemia/lymphoma. Anticancer
Res. 34:5287–5294. 2014.PubMed/NCBI
|
|
56
|
Elhag R, Mazzio EA and Soliman KF: The
effect of silibinin in enhancing toxicity of temozolomide and
etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Anticancer Res. 35:1263–1269. 2015.PubMed/NCBI
|
|
57
|
Olivier S, Robe P and Bours V: Can
NF-kappaB be a target for novel and efficient anti-cancer agents?
Biochem Pharmacol. 72:1054–1068. 2006. View Article : Google Scholar : PubMed/NCBI
|
